Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
The independent source for health policy research, polling, and news.
381-400 of 483 results
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
Stephanie Armour of The Wall Street Journal, Alice Ollstein of Politico and Rebecca Adams of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss the suggested cuts to health programs in President Donald Trump鈥檚 budget proposal, the latest on lawsuits challenging work requirements for Medicaid enrollees and the FDA鈥檚 crackdown on e-cigarettes. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week.
The FDA said it might reclassify the widely used devices featured in a recent Kaiser Health News investigation.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
The Food and Drug Administration has let medical device companies file reports of injuries and malfunctions outside a widely scrutinized public database, leaving doctors and medical sleuths in the dark.
The Food and Drug Administration claims CanaRX, a company used by more than 500 cities, counties and school districts to help their employees get cheaper drugs from overseas, has sent 鈥渦napproved鈥� and 鈥渕isbranded鈥� drugs to U.S. consumers, jeopardizing their safety.
Doctors and patients say they鈥檙e compelled to use off-label meds as research goes unfunded.
High-profile failures of implantable medical devices 鈥� such as certain hip joints and pelvic mesh 鈥� have prompted the Food and Drug Administration to revise its assessment process.
Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Anna Edney of Bloomberg News join KHN鈥檚 Julie Rovner to discuss the latest national health spending estimates, another FDA crackdown on dietary supplements and lawsuits between insurers and the federal government that could result in a windfall for consumers.
The race for the cure to aging sparks hope and hype among top scientists 鈥� plus billions of dollars in investment.
The Michigan Democrat chaired the House Energy and Commerce Committee and his impact on health care was immense.
President Donald Trump and FDA officials have pointed to a surge in generic drug approvals, but a data analysis indicates almost half haven鈥檛 reached the market.
Democratic governors and mayors are unveiling new ideas to control costs and expand coverage. The federal government shutdown has spared most health agencies, but not all. And learn the latest on that lawsuit out of Texas, which is threatening the Affordable Care Act once again. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss these issues and, for 鈥渆xtra credit,鈥� provide their favorite health policy stories of the week. Rovner also interviews KHN鈥檚 Jordan Rau about the latest 鈥淏ill of the Month.鈥�
Critics say patients are often misled by ads that advocate high-priced drugs or genetic tests.
The Food and Drug Administration is supposed to inspect all factories, foreign and domestic, that produce drugs for the U.S. market. But a KHN review of thousands of FDA documents 鈥� inspection records, recalls, warning letters and lawsuits 鈥� reveals how drugs that are poorly manufactured or contaminated can reach consumers.
Medicare and Medicaid are fine, but the food safety component of the Food and Drug Administration and bio-threat surveillance done by the Department of Homeland Security are among the public health functions feeling the pinch.
There could be a long legal struggle ahead over the decision by a judge in Texas to invalidate the federal health law. But if his decision stands, it would have long-lasting effects on health care from insurance coverage to Medicare payments to privacy protections.
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from 鈥渂iosimilars.鈥� It鈥檚 a very different story in Europe.
The new-generation gadget is designed to alert and protect wearers from falls and heart problems, expanding Apple鈥檚 target audience beyond the usual, tech-savvy, early adopters to those with older tickers.
A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.
漏 2026 KFF